Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 378

1.

Post-treatment control of HIV infection.

Conway JM, Perelson AS.

Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5467-72. doi: 10.1073/pnas.1419162112. Epub 2015 Apr 13.

PMID:
25870266
2.

Quantification of HCV cell-to-cell spread using a stochastic modeling approach.

Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H.

J Virol. 2015 Apr 1. pii: JVI.00016-15. [Epub ahead of print]

PMID:
25833046
3.

Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo.

Smith NM, Mlcochova P, Watters SA, Aasa-Chapman MM, Rabin N, Moore S, Edwards SG, Garson JA, Grant PR, Ferns RB, Kashuba A, Mayor NP, Schellekens J, Marsh SG, McMichael AJ, Perelson AS, Pillay D, Goonetilleke N, Gupta RK.

Clin Infect Dis. 2015 Mar 16. pii: civ219. [Epub ahead of print]

PMID:
25778749
4.

Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.

Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, Rong R, Claiborne DT, Prince JL, Tang J, Ribeiro RM, Cormier E, Hahn BH, Perelson AS, Shaw GM, Karita E, Gilmour J, Goepfert P, Derdeyn CA, Allen SA, Borrow P, Hunter E.

PLoS Pathog. 2015 Jan 8;11(1):e1004565. doi: 10.1371/journal.ppat.1004565. eCollection 2015 Jan.

5.

Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation.

Liu D, Zuo T, Hora B, Song H, Kong W, Yu X, Goonetilleke N, Bhattacharya T, Perelson AS, Haynes BF, McMichael AJ, Gao F.

Retrovirology. 2014 Nov 19;11(1):101. doi: 10.1186/s12977-014-0101-0.

6.

Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes.

Graw F, Balagopal A, Kandathil AJ, Ray SC, Thomas DL, Ribeiro RM, Perelson AS.

PLoS Comput Biol. 2014 Nov 13;10(11):e1003934. doi: 10.1371/journal.pcbi.1003934. eCollection 2014 Nov.

7.

Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells.

Althaus CL, Joos B, Perelson AS, Günthard HF.

PLoS Comput Biol. 2014 Oct 23;10(10):e1003871. doi: 10.1371/journal.pcbi.1003871. eCollection 2014 Oct.

8.

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.

Canini L, Chatterjee A, Guedj J, Lemenuel-Diot A, Brennan B, Smith PF, Perelson AS.

Antivir Ther. 2014 Oct 16. doi: 10.3851/IMP2879. [Epub ahead of print]

PMID:
25321394
9.

Modeling the dynamics and migratory pathways of virus-specific antibody-secreting cell populations in primary influenza infection.

Miao H, Sangster MY, Livingstone AM, Hilchey SP, Zhang L, Topham DJ, Mosmann TR, Holden-Wiltse J, Perelson AS, Wu H, Zand MS.

PLoS One. 2014 Aug 29;9(8):e104781. doi: 10.1371/journal.pone.0104781. eCollection 2014.

10.

A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.

Conway JM, Perelson AS.

PLoS Comput Biol. 2014 Aug 7;10(8):e1003769. doi: 10.1371/journal.pcbi.1003769. eCollection 2014 Aug.

11.

Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

Sherman KE, Guedj J, Shata MT, Blackard JT, Rouster SD, Castro M, Feinberg J, Sterling RK, Goodman Z, Aronow BJ, Perelson AS.

Sci Transl Med. 2014 Jul 23;6(246):246ra98. doi: 10.1126/scitranslmed.3008195.

12.

Antibody responses during hepatitis B viral infection.

Ciupe SM, Ribeiro RM, Perelson AS.

PLoS Comput Biol. 2014 Jul 31;10(7):e1003730. doi: 10.1371/journal.pcbi.1003730. eCollection 2014 Jul.

13.

Reversion and T cell escape mutations compensate the fitness loss of a CD8+ T cell escape mutant in their cognate transmitted/founder virus.

Song H, Hora B, Bhattacharya T, Goonetilleke N, Liu MK, Wiehe K, Li H, Iyer SS, McMichael AJ, Perelson AS, Gao F.

PLoS One. 2014 Jul 16;9(7):e102734. doi: 10.1371/journal.pone.0102734. eCollection 2014.

14.

Viral kinetic modeling: state of the art.

Canini L, Perelson AS.

J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):431-43. doi: 10.1007/s10928-014-9363-3. Epub 2014 Jun 25.

PMID:
24961742
15.

Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H.

Antivir Ther. 2015;20(2):149-55. doi: 10.3851/IMP2806. Epub 2014 Jun 10.

PMID:
24912382
16.

Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study.

Canini L, Conway JM, Perelson AS, Carrat F.

PLoS Comput Biol. 2014 Apr 17;10(4):e1003568. doi: 10.1371/journal.pcbi.1003568. eCollection 2014 Apr. Erratum in: PLoS Comput Biol. 2014 Jun;10(6):e1003699.

17.

Effects of aging on influenza virus infection dynamics.

Hernandez-Vargas EA, Wilk E, Canini L, Toapanta FR, Binder SC, Uvarovskii A, Ross TM, Guzmán CA, Perelson AS, Meyer-Hermann M.

J Virol. 2014 Apr;88(8):4123-31. doi: 10.1128/JVI.03644-13. Epub 2014 Jan 29.

18.

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12. doi: 10.1073/pnas.1318249111. Epub 2014 Jan 27.

19.

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.

Guedj J, Pang PS, Denning J, Rodriguez-Torres M, Lawitz E, Symonds W, Perelson AS.

Antivir Ther. 2014;19(2):211-20. doi: 10.3851/IMP2733. Epub 2014 Jan 24.

PMID:
24464551
20.

Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.

Rong L, Guedj J, Dahari H, Perelson AS.

Antivir Ther. 2014;19(5):469-77. doi: 10.3851/IMP2725. Epub 2014 Jan 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk